These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12135803)

  • 1. Advances in prenatal screening for Down syndrome: I. general principles and second trimester testing.
    Benn PA
    Clin Chim Acta; 2002 Sep; 323(1-2):1-16. PubMed ID: 12135803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age.
    Bahado-Singh RO; Oz AU; Kovanci E; Deren O; Copel J; Baumgarten A; Mahoney J
    Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1627-31. PubMed ID: 9855608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study.
    Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A
    Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions.
    Benn PA
    Clin Chim Acta; 2002 Oct; 324(1-2):1-11. PubMed ID: 12204419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined second-trimester biochemical and ultrasound screening for Down syndrome.
    Benn PA; Kaminsky LM; Ying J; Borgida AF; Egan JF
    Obstet Gynecol; 2002 Dec; 100(6):1168-76. PubMed ID: 12468159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-trimester maternal serum screening for Down's syndrome: free beta-human chorionic gonadotrophin (HCG) and alpha-fetoprotein, with or without unconjugated oestriol, compared with total HCG, alpha-fetoprotein and unconjugated oestriol.
    Extermann P; Bischof P; Marguerat P; Mermillod B
    Hum Reprod; 1998 Jan; 13(1):220-3. PubMed ID: 9512261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical strategies in contingent sequential screening for Down syndrome.
    Benn P; Wright D; Cuckle H
    Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second trimester serum markers.
    Canick JA; MacRae AR
    Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
    Biggio JR; Morris TC; Owen J; Stringer JS
    Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.